Seroatlas · Human Serome Atlas

KCNA2

Potassium voltage-gated channel subfamily A member 2

Also known as: HK4, KCNA2_HUMAN, Kv1.2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P16389
Gene
KCNA2
Ensembl
ENSG00000177301
Chromosome
1
Canonical length
499 aa
Protein class
Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels
Quaternary structure
Homotetramer

OverviewNCBI Gene

Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. It belongs to the delayed rectifier class, members of which allow nerve cells to efficiently repolarize following an action potential. The coding region of this gene is intronless, and the gene is clustered with genes KCNA3 and KCNA10 on chromosome 1. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

499 residues, UniProt reviewed canonical sequence.

>P16389|KCNA2
     1  MTVATGDPAD EAAALPGHPQ DTYDPEADHE CCERVVINIS GLRFETQLKT LAQFPETLLG
    61  DPKKRMRYFD PLRNEYFFDR NRPSFDAILY YYQSGGRLRR PVNVPLDIFS EEIRFYELGE
   121  EAMEMFREDE GYIKEEERPL PENEFQRQVW LLFEYPESSG PARIIAIVSV MVILISIVSF
   181  CLETLPIFRD ENEDMHGSGV TFHTYSNSTI GYQQSTSFTD PFFIVETLCI IWFSFEFLVR
   241  FFACPSKAGF FTNIMNIIDI VAIIPYFITL GTELAEKPED AQQGQQAMSL AILRVIRLVR
   301  VFRIFKLSRH SKGLQILGQT LKASMRELGL LIFFLFIGVI LFSSAVYFAE ADERESQFPS
   361  IPDAFWWAVV SMTTVGYGDM VPTTIGGKIV GSLCAIAGVL TIALPVPVIV SNFNYFYHRE
   421  TEGEEQAQYL QVTSCPKIPS SPDLKKSRSA STISKSDYME IQEGVNNSNE DFREENLKTA
   481  NCTLANTNYV NITKMLTDV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against KCNA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
6
Mean surface accessibility (rSASA)
0.41
Highest tissue expression
34 nTPM

Expression across tissuesHPA

Tissue

  • cerebellum: 34 nTPM
  • cerebral cortex: 31 nTPM
  • basal ganglia: 14 nTPM
  • hippocampal formation: 11 nTPM
  • amygdala: 11 nTPM
  • midbrain: 9.9 nTPM

Single-cell type

  • astrocytes: 55 nCPM
  • oligodendrocyte progenitor cells: 43 nCPM
  • early spermatids: 38 nCPM
  • brain inhibitory neurons: 33 nCPM
  • brain excitatory neurons: 30 nCPM
  • bergmann glia: 29 nCPM

Immune cell

  • T-reg: 1.3 nTPM
  • memory CD4 T-cell: 0.5 nTPM
  • memory CD8 T-cell: 0.3 nTPM
  • naive CD4 T-cell: 0.2 nTPM
  • gdT-cell: 0.1 nTPM
  • MAIT T-cell: 0.1 nTPM

Brain region

  • cerebral cortex: 229 nTPM
  • pons: 127 nTPM
  • thalamus: 110 nTPM
  • white matter: 101 nTPM
  • medulla oblongata: 86 nTPM
  • hypothalamus: 85 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about KCNA2.

Disease | AllUniProt

Conditions KCNA2 is implicated in, by any mechanism.

  • Developmental and epileptic encephalopathy 32 (DEE32) MIM:616366
  • Nizon-Isidor syndrome (NIZIDS) MIM:618872

Disease | GeneticClinVar

64 pathogenic / likely-pathogenic of 578 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on KCNA2 was assayed in.

ReferencesPubMed · IEDB

Publications for KCNA2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

3 publications

Reference: B cellIEDB

1 publication

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.38
gnomAD pLI
0.91
gnomAD missense Z
3.83
DepMap mean gene effect
0
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of KCNA2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads KCNA2 as an antibody target. Whether an autoantibody or antibody against KCNA2 could matter depends on whether native KCNA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

KCNA2 is annotated at the cell surface, where native KCNA2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label KCNA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/KCNA2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...